title: Should Domperidone be Used as a Galactagogue? Possible Safety Implications for Mother and Child.
abstract: Domperidone has been used as a galactagogue; however, solid evidence from an adequate sized randomized clinical trial is missing. Optimal dosage, start of treatment, length of treatment and scope of patients who can benefit also remain unknown. Although milk obtained after domperidone administration has not been shown to have untoward effects on newborns, no sufficiently large randomized clinical trial has been done to establish safety. Domperidone has repeatedly been shown to produce sudden cardiac death, starting at 30 mg/day. Because of this known cardiac effect, the use of domperidone to increase breast milk production may not be justified.
authors.affiliation: HPC n.v. Pharmacology, Westlaan 85, 8400, Ostend, Belgium. Luc.Hondeghem@ScreenQT.com.
authors.forename: Luc M
authors.initials: LM
authors.lastname: Hondeghem
authors.affiliation: , Weststraat 55A, 8800, Roeselare, Belgium.
authors.forename: Noël H
authors.initials: NH
authors.lastname: Logghe
mesh_terms: D001942:Breast Feeding; D016757:Death, Sudden, Cardiac / Q000453:epidemiology / Q000209:etiology*; D004294:Domperidone / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D056669:Galactogogues / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D009035:Mothers; D016032:Randomized Controlled Trials as Topic
chemical_list: D056669:Galactogogues; D004294:Domperidone